Home » Stocks » Kymera Therapeutics

Kymera Therapeutics, Inc. (KYMR)

Stock Price: $29.22 USD -1.42 (-4.63%)
Updated Sep 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.30B
Revenue (ttm) 9.50M
Net Income (ttm) -47.85M
Shares Out 44.44M
EPS (ttm) -1.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 21, 2020
Last Price $29.22
Previous Close $30.64
Change ($) -1.42
Change (%) -4.63%
Day's Open 30.16
Day's Range 28.61 - 31.14
Day's Volume 255,602
52-Week Range 25.43 - 37.75

More Stats

Market Cap 1.30B
Enterprise Value 1.16B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 44.44M
Float 22.92M
EPS (basic) n/a
EPS (diluted) -1.15
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 196,509
Short Ratio 0.21
Short % of Float 0.60%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 136.71
PB Ratio 12.42
Revenue 9.50M
Operating Income n/a
Net Income -47.85M
Free Cash Flow n/a
Net Cash 136.86M
Net Cash / Share 3.08
Gross Margin -360.29%
Operating Margin n/a
Profit Margin -503.78%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$34.67*
(18.65% upside)
Low
27.0
Current: $29.22
High
42.0
Target: 34.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue2.93-
Gross Profit2.93-
Operating Income-42.21-21.45
Net Income-41.25-21.47
Shares Outstanding2.711.88
Earnings Per Share-15.23-11.45
Operating Cash Flow17.91-17.86
Capital Expenditures-0.53-1.36
Free Cash Flow17.37-19.22
Cash & Equivalents91.9641.26
Total Debt21.190.70
Net Cash / Debt70.7640.57
Assets11744.23
Liabilities82.035.24
Book Value-74.41-34.44
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kymera Therapeutics, Inc.
Country United States
Employees 55
CEO Nello Mainolfi

Stock Information

Ticker Symbol KYMR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KYMR
IPO Date August 21, 2020

Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.